Aspirin and stroke prevention

Area of Science:

• Cardiovascular Medicine
• Neurology
• Pharmacology

Background:

• Aspirin is a widely used antiplatelet agent for preventing vascular events.
• Its efficacy and optimal dosage in various arterial diseases, particularly ischemic cerebrovascular disease, require ongoing evaluation.
• Comparative effectiveness against other antiplatelet agents remains a key area of research.

Purpose of the Study:

• To analyze the efficacy of aspirin in reducing major vascular events across different arterial disease populations.
• To compare aspirin's effectiveness with other antiplatelet agents.
• To investigate the relationship between aspirin dosage and both efficacy and side effects.

Main Methods:

• Meta-analysis of existing studies on aspirin and other antiplatelet agents.
• Comparison of relative risk reduction for vascular events in different patient groups.
• Evaluation of dose-response relationships for aspirin efficacy and safety.

Main Results:

• Aspirin shows a 19% relative risk reduction in major vascular events for general arterial disease, but only 13% for ischemic cerebrovascular disease.
• No significant difference in efficacy was found across a wide range of aspirin doses (30-1300 mg daily).
• Higher aspirin doses are associated with increased frequency of side effects. Other antiplatelet agents offer no clear advantage over aspirin.

Conclusions:

• The observed difference in aspirin's efficacy between general arterial disease and ischemic cerebrovascular disease may stem from pathophysiological differences.
• Aspirin dosage can be individualized within a broad range (75-1300 mg) without compromising efficacy, while minimizing side effects.
• Recurrent TIAs during aspirin therapy warrant diagnostic review rather than immediate antiplatelet agent switching.